A Phase 3, Multicenter, Randomized, Blinded, Controlled Study of NV-101 for Efficacy and Safety in Patients Undergoing Simple Maxillary Dental Procedures

Grants and Contracts Details

StatusFinished
Effective start/end date4/15/054/30/07

Funding

  • Nova Pharmaceuticals: $13,068.00